This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The formulation is backed by over 80 clinical trials and 200 scientific publications
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
The move is expected to be crucial during health crises
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
The initiative aims to connect startups and tech companies with its business units,
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Subscribe To Our Newsletter & Stay Updated